- Meet Vect-Horus at BIO Japan
- Vect-Horus will be attending the BiotechShowcase 23
- 11th International Conference on Cerebral Vascular Biology
- 3rd Annual RNAi-Based Therapeutics Summit from April 19th to 21th, 2022, in Boston
- 3rd Edition of Translational neuroscience Day : challenges and opportunities
- 8th Edition of BioFIT for the first time in MARSEILLE
- AAT-AD/PD Focus Meeting, TORINO Italy
- AD/PD 2019 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders in LISBON
- BIO International Convention in BOSTON, MA
- Biopharm America 2015
- BiotechShowcase
- Blood Brain Barrier Summit delivered digitally
- Boulder Peptide Symposium
- CNS Barrier Congress
- e-Meet Vect-Horus at the digital BIO Europe Spring
- e-Meet Vect-Horus at the digital BIO Europe Spring from March 28 to 31, 2022
- e-Meet Vect-Horus at the digital BIO International
- e-Meet Vect-Horus at the digital BIO Spring Paris
- Early September VECT-HORUS’ team will be attending the EANM2023 Annual Congress!
- ECMED EU-GliaPhD international conference in MALTA
- Festival of Biologics 2019 in BASEL
- Fifth round of funding
- Fourth round of financing
- Gerhard Levy Distinguished Lectureship in Pharmaceutical Sciences for Prof. Scherrmann, chairman of Vect-Horus’ Scientific Advisory Board
- Happy new year !
- Happy new year !
- Happy new year !
- How blood–brain barrier technology is unleashing CNS therapies
- LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma
- Meet Vect-Horus at 3rd Oligonucleotides for CNS Summit in Boston June 6-8th, 2023
- Meet Vect-Horus at BIO Europe Berlin
- Meet Vect-Horus at BIO Europe Cologne
- Meet Vect-Horus at BIO Europe Copenhagen
- Meet Vect-Horus at BIO Europe Digital
- Meet Vect-Horus at BIO Europe Digital
- Meet Vect-Horus at BIO Europe HAMBURG
- Meet Vect-Horus at BIO International
- Meet Vect-Horus at BIO International in Boston June 5-8, 2023
- Meet Vect-Horus at BIO International in San Diego June 14-18, 2022
- Meet Vect-Horus at BIO Spring Amsterdam
- Meet Vect-Horus at BIO Spring Barcelona
- Meet Vect-Horus at BIO Spring Basel, Switzerland, March 20–22, 2023
- Meet Vect-Horus at BIO Spring Vienna
- Meet Vect-Horus at BIO-Europe Spring® 2015
- Meet Vect-Horus at BIOTECH SHOWCASE, San Francisco, January 8-10, 2024
- Meet Vect-Horus at OTS, Barcelona, October 22-25, 2023
- Meet Vect-Horus at OTS, Montreal, October 6-9, 2024
- Meet Vect-Horus at San Diego, California, June 3-6, 2024
- Meet Vect-Horus at the 36th PAMM-EORTC Winter meeting
- Meet Vect-Horus at the 3rd Annual Next Gen Lipid-Based Nanoparticles Delivery Summit, Boston, August 21-23, 2024
- Meet Vect-Horus at TIDES Europe in Vienna from November 16th to 18th, 2022.
- mRNA Based Therapeutics poster
- Nanomedicine for treating cancer and brain diseases symposium in MARSEILLE
- Neurotensin, vectorised by VECT-HORUS, is the first drug-candidate in neuroprotective hypothermia
- New PCT patent application covering anti Transferrin receptor vectors
- NTSR2 is induced in astrocytes and brain endothelial cells in relation to neuroinflammation following pilocarpine-induced seizures in rats
- Oligonucleotides for CNS Congress from February 22-24, 2021
- Participation au BIOREZO™ Vectorisation : de l’imagerie à la thérapeutique
- Poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting
- RadioMedix and Vect-Horus announce first dosing of Glioblastoma Multiforme and Pancreatic ductal adenocarcinoma patients with 68Ga-RMX-VH
- Relocation of the company to support its development
- RIB 2016 PARIS – Neurological Disorders
- Selected for a 5’ Pitch at the 2nd edition of the TOULOUSE ONCO WEEK
- Selected for an Elevator Pitch at the 3rd edition of MEET2WIN
- Séminaire M&M’s – Muscle Monday Seminars of the Institute’s Myology Centre for Research on January 17, 2022
- Signature of a Research Common Lab with the Institute for NeuroPhysiopathology (UMR7051 CNRS-AMU)
- Society for the study of Blood-Brain interfaces SEISC 2019 congres
- TIDES Asia, March 2-5 2021 - 100% Virtual
- TIDES Europe, Nov. 11-13, 2020 - 100% Virtual
- TIDES Europe: Oligonucleotide & Peptide Therapeutics in AMSTERDAM
- Two new patents protecting VECTrans® technology issued in several major countries
- Two research groups specialized in CNS drug delivery and in the development of therapeutic strategies for glioblastoma give in vivo POC on one of the peptide vectors described by Vect-Horus
- Vect-Horus and Cerimed announce collaboration to support the development of its theragnostic agents
- Vect-Horus and its academic partners describe the chemical optimisation of one of its lead peptides (Malcor et al., 2012, J Med Chem)
- Vect-Horus and RadioMedix Announce FDA Approval of Exploratory IND of Diagnostic 68 Ga-RMX-VH in Glioblastoma Multiforme
- Vect-Horus and RadioMedix announce the signing of a LOI to co-develop a Vect-Horus’ radio-theranostic agent for Glioblastoma
- Vect-Horus announces a new equity issue of 1.5 M€ to finance the preclinical development of its first vectorized product
- Vect-Horus announces agreement with Johnson&Johnson Innovation
- Vect-Horus announces Collaboration and Option Agreement with ASTELLAS Pharma
- Vect-Horus announces the expansion of its Scientific Advisory Board
- Vect-Horus announces the signing of a scientific collaboration agreement with SANOFI in the field of neurodegenerative diseases
- Vect-Horus announces the signing of a scientific collaboration agreement with SERVIER
- Vect-Horus appoints Dr Jamal Temsamani as Director of Drug Development & Corporate
- Vect-Horus Appoints Dr Jean-Manuel PEAN as Chief Scientific Officer
- Vect-Horus at Pierre Fabre DayOne Open Innovation Day
- Vect-Horus attends to the NLSDays
- Vect-Horus completes its €12 Million fund-raising operation
- Vect-Horus confirmed to attend BioPharm America 2017
- Vect-Horus demonstrates the high versatility of its peptide-vectors library for a targeted delivery of small molecules and protein cargos
- Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases
- Vect-Horus Enters Exclusive License Agreement with Novo Nordisk to Develop Targeted Therapeutics
- Vect-Horus enters into Collaboration and License Agreement with ONO Pharmaceutical Co., Ltd.
- Vect-Horus focuses on Target engagement and intracellular delivery of LDLR conjugates to design new targeted drug therapies
- Vect-Horus further strengthens leadership with appointment of strategy and finance executive Jérôme Berger to its Board of Directors
- Vect-Horus has been honored with a prestigious European Enterprise Award
- Vect-Horus is a partner laureate of the ANR MALZ 2010 call for proposals
- Vect-Horus is a partner laureate of the ANR MALZ 2011 call for proposals
- Vect-Horus is a partner laureate of the ANR RPIB Call 2013 for proposals
- Vect-Horus is one of the CNRS 15 success stories
- Vect-Horus Nominated for the 2024 Biotech Trophy Award, Organized by France Biotech
- Vect-Horus one the 50 Best Companies to Watch 2020 according to the Silicon Review magazine
- Vect-Horus participates to the event Radiopharmaceuticals & Imaging on March 14, 2023
- Vect-Horus poursuit le renforcement son équipe de direction en nommant Carole Imbert au poste de Directrice Financière
- Vect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to Organs and Tumors
- Vect-Horus raises 2.5 M€ to finance its development projects in the “targeted therapy” field
- Vect-Horus raises 3.5M€ to accelerate its development programs
- Vect-Horus raises €6.7 Million to further develop its VECTrans® Platform
- Vect-Horus receives the Frost & Sullivan 2016 Leadership award
- VECT-HORUS recognized as a newcomer to the theranostic field by Labiotech
- Vect-Horus reçoit un financement non dilutif de 1M(e) dans le cadre du dispositif de relance Européen REACT-EU
- Vect-Horus reçoit une subvention pour le développement de sa plateforme VECTrans® dans le domaine de l’ophtalmologie
- Vect-Horus rejoint la communauté Bpifrance Excellence
- Vect-Horus Strengthens Board of Directors with Appointment of Jean-Christophe Dantonel as New Member
- Vect-Horus strengthens its scientific advisory board with the appointment of Dr. Julia ALTERMAN
- Vect-Horus strengthens its scientific advisory board with the appointment of Frédéric MATONTI
- Vect-Horus successfully completes the VECtoBrain project
- Vect-Horus team will attend the 8AIS2020 symposium from Nov. 23-26, 2020
- Vect-Horus validates the potential of its peptide vectors to transport proteins or antibodies, across the blood-brain barrier via receptor mediated transport
- Vect-Horus will attend BIO International Convention in PHILADELPHIA
- Vect-Horus will attend the Biorezo “Nouvelles technologies de vectorisation, perspectives pour les biotechs et pharma”
- Vect-Horus will attend to BioJapan Digital Conference
- Vect-Horus will be attending BIO Europe from the 24th - 26th October in Germany
- Vect-Horus will be attending the #EANM 2022 Annual Congress
- Vect-Horus will be attending the EANM’18 Congress in Düsseldorf
- Vect-Horus will be attending the EANM’19 Congress in Barcelona
- Vect-Horus will be attending the J.P. Morgan 36th Annual Healthcare Conference
- Vect-Horus will join the ARVO Annual Meeting
- Vect-Horus will join the Single-Domain Antibodies Summit
- Vect-Horus will participate to the event “Espace & Santé” co-organized by CNES, Region Paca and DHUNE on March 29, 2022
- Vect-Horus will participate to the HealthTech Innovation Days on November 13-14, 2022
- Vect-Horus will participate to the “R&D Seminar IMAGING 2022” organized by the Cerimed September 26-30, 2022
- Vect-Horus will present at Delivery of Macromolecules, June 8, 2022
- Vect-Horus, AAA form scientific collaboration to open new avenues in treatment of brain diseases
- Vect-Horus: Top Drug Discovery and Development Europe Companies
